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Case Report

RV lead placement – A forgotten cause of right heart failure
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Introduction: Cardiac implantable electronic devices (CIEDs) have opened new doors, improving the quality, and
increasing the duration of life by providing support of heart rate, atrioventricular and interventricular synchrony,
thereby preventing sudden cardiac death. Nevertheless, these devices can pose some risks to the patients,
including pacemaker-mediated cardiomyopathy and endocarditis.
Case presentation: We elucidate the case of a patient who had severe Tricuspid Regurgitation as a result of single
chamber Implantable Cardioverter Defibrillator (ICD) placement which led to right heart failure (RHF). His chief
complaints were generalized fatigability and difficulty climbing steps at home. He also had orthopnea but denies
paroxysmal nocturnal dyspnea. Despite using home diuretic regimen (Torsemide 40 gm daily), his continued to
increase. He did not respond well to intravenous diuretics that time so decision was made to start Aquapheresis to
which he responded very well
Discussion: TV dysfunction associated with CIED leads can be investigated and diagnosed using different tech
niques. These pillars of diagnostic tests include two-dimensional (2D), 3D, and Doppler echocardiography.
Presence of holosystolic hepatic vein flow reversal is key in diagnosing severe TR, whereas normal antegrade
systolic flow excludes the possibility of moderate and severe TR.
Conclusion: CIED leads causing tricuspid valve impairment has become increasingly recognized over the recent
times; however, the evidence underlying this trend has been derived primarily from retrospective analyses. In
order to circumvent these issues, leadless pacemakers and subcutaneous ICD devices should be considered.

1. Introduction
Cardiac implantable electronic devices (CIEDs) have opened new
doors, improving the quality and increasing the duration of life by
providing support of heart rate, atrioventricular and interventricular
synchrony, thereby preventing sudden cardiac death [1]. These devices
continuously monitor cardiac rhythm and if these devices encounter
VT/VF, a shock is promptly delivered to terminate the episode. These
devices can pose some risks to the patients like pacemaker mediated
cardiomyopathy and endocarditis. We elucidate the case of a patient
who had severe Tricuspid Regurgitation as a result of single chamber
Implantable Cardioverter Defibrillator (ICD) placement which led to
right heart failure (RHF).
2. Case presentation
A 79 year old man with was referred to the emergency room by his

primary care physician for worsening shortness of breath going on for 4
weeks. He had previous medical history significant for non-ischemic
cardiomyopathy (Ejection Fraction 35%) status post single chamber
ICD placement 3 years ago, permanent atrial fibrillation not on anti
coagulation due to history of intracranial bleed, hypertension and type 2
Diabetes. His main complaints were generalized fatigability and diffi
culty climbing steps at home. He also had orthopnea but denies parox
ysmal nocturnal dyspnea. Inspite of using home diuretic regimen
(Torsemide 40 gm daily), his weight kept on increasing. He was
compliant with salt and fluid restriction. He was found to be almost 40
pounds overweight from his baseline. He had jugular venous distension
and significant lower extremity edema on examination. His blood work
was significant for normal renal function, hepatic function and cardiac
BNP was 1109 pg/ml. Chest Xray (Fig. 1) showed large right sided
pleural effusion which was tapped and found to be transudative. His
EKG (Fig. 2) showed atrial fibrillation and left axis deviation.
Transthoracic echocardiogram showed 50–55% left ventricular
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showed elevated filling pressures. He did not respond well to intrave
nous diuretics that time so decision was made to start Aquapheresis to
which he responded very well. His transthoracic echocardiogram
showed further worsening of TR and severely enlarged right atrium/
right ventricle. His ejection fraction was found to be preserved.
The patient was followed in the clinic. He was followed up monthly
for 1st two months and then advised to follow up every 6 months. Device
was interrogated at every visit and no inappropriate therapy was found
to be delivered.
3. Discussion
Right heart failure (RHF) is a clinical syndrome characterised by
symptoms and signs, that arise as a result of dysfunctioning of right heart
structures including the right ventricle and the tricuspid valve, leading
to decreased ability of the right heart to supply blood to the lungs at
normal central venous pressures [2]. Right heart failure can be an acute
or chronic process and its aetiology comprises acquired or congenital
forms of cardiovascular disease (Fig. 5).
Acute right heart failure can occur due to RV infarction, myocarditis
or from pulmonary embolism while the causes of chronic RHF are listed
in Table 1.
Normal pulmonary circulation is a low resistance, high-compliance
system that accommodates a large volume of blood flow with minimal
increase in pressures under normal conditions. Right ventricle normally
ejects blood at very low pressure, as compared with the much thickerwalled LV. Thus, the RV is generally far more afterload sensitive than
the LV. For this reason, acute increases in pulmonary artery (PA) pres
sure, such as that caused by acute pulmonary embolism, may precipitate
cardiogenic shock because the RV cannot generate sufficient pressure to
maintain pulmonary perfusion. With chronic, sustained increases in PA
pressure there are hypertrophic adaptations in the RV that allow for
maintenance of forward flow despite the increase in RV afterload.
Overtime, this adaptive hypertrophy progresses and becomes mal
adaptive, leading to RV dilation and progressive myocardial dysfunc
tion. With increasing RV volumes, there is dilation of the tricuspid valve
apparatus, precipitating functional tricuspid regurgitation. This further
increases the right atrium volume load and RV, promoting further
dilation and increasing severity of tricuspid regurgitation as part of a
ferocious chain of events. Atrial fibrillation often develops in the setting
of progressive atrial enlargement, but the relationship is bidirectional, as
atrial fibrillation also leads to worsening RV dysfunction.
Impaired RV systolic function, increasing tricuspid valve regurgita
tion, and impaired LV filling reduce forward stroke volume and cardiac
output. This leads to neurohormonal activation that promotes renal
sodium and water retention. The consequent volume overload and
myocardial dysfunction cause marked elevation in central venous
pressure. This leads to an increase in tissue hydrostatic pressures in and
decreases lymph flow. Systemic venous hypertension in the body results
in gut and lower extremity edema, ascites, and liver dysfunction from
congestive hepatopathy that may progress to cirrhosis. Increases in

Fig. 1. Chest X-ray divulging a large right-sided pleural effusion.

Fig. 2. EKG demonstrating a classical atrial fibrillation pattern with left
axis deviation.

ejection fraction, mildly reduced right ventricular systolic dysfunction
and moderate tricuspid regurgitation resulting in moderate pulmonary
hypertension. Echocardiogram a year before ICD placement showed
trivial TR (Figs. 3 and 4). Right heart catheterization (RHC) showed
severely elevated right sided pressures with normal pulmonary vascular
resistance. He responded well to intravenous diuretics. His ICD inter
rogation revealed 22% RV pacing. His heart rate remained in 70–80
beats/minute. He was discharged from the hospital in stable condition.
After few months, he was admitted again in the hospital with refractory
volume overload (30 pounds above his baseline weight). Again, RHC

Fig. 3. Color & spectral Doppler showing minimal TR. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of
this article.)
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Fig. 4. Color & spectral Doppler showing moderate to severe TR. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web
version of this article.)

Fig. 5. Ventricular interdependence in chronic right heart failure.
Table 1
A tabulation of the established causes of right heart failure.
Volume Overload

Pressure Overload

Tricuspid Regurgitation
Pulmonary Regurgitation
Transposition of Great Vessels

Left sided heart failure
Pulmonary hypertension

Fig. 6. A delineation of the anatomy of the tricuspid valve.

gets poorer with increasing severity, with age, right ventricular size,
biventricular systolic function, and dilation of the inferior vena cava
bearing little effect of the prognosis [3].
Tricuspid valve leaflets or sub-valvular structures can be compro
mised/damaged during lead implantation or manipulation, in a myriad
of forms, and it may not be picked by follow up routine imaging. These
forms of structural damage include: leaflet perforation, avulsion which
may occur during extraction of leads, laceration and transection of
chordal structures or papillary muscles. After implantation of a CIED,
mechanical interference with TV leaflet movement and coaptation can
cause tricuspid regurgitation. A lead traversing the TV can thwart leaflet
coaptation in two ways: direct contact with the leaflets or entwining
with chordae tendineae [4–6]. TV dysfunction associated with CIED
leads can be investigated and diagnosed using different techniques.
These pillars of diagnostic tests include two-dimensional (2D), 3D, and
Doppler echocardiography. Presence of holosystolic hepatic vein flow
reversal is key in diagnosing severe TR, whereas normal antegrade
systolic flow excludes the possibility of moderate and severe TR [7].
Currently, many studies are being conducted to compare transvenous
versus subcutaneous ICDs [8–10]. The PRAETORIAN trial is a random
ized, controlled noninferiority trial which compared two types of ICDs.
At 48 months, the estimated cumulative incidence of the primary end
point (composite of device-related complications and inappropriate
shocks) was 15.1% in the subcutaneous ICD group and 15.7% in the
transvenous ICD group (hazard ratio, 0.99; 95% confidence interval,
0.71 to 1.39; P = 0.01 for noninferiority). There was no significant
difference between the two groups regarding the secondary end point of
death from any cause. The trial showed that both systems were quite
effective at terminating malignant arrhythmias. The trial showed that
both systems were quite effective at terminating malignant arrhythmias.
However, complications, including lead malfunction and infection, were

central venous pressure also increase renal vein pressure and play a key
role in promoting cardiorenal syndrome.
Most patients with RHF typically have history of known left-sided
HF, pulmonary diseases like COPD or obstructive sleep apnea but
some patients present with symptoms and signs of RHF (unexplained
ascites or dyspnea) without these obvious etiologies. Currently, the
universal requirement, involving the use of an endocardial lead for
pacing or defibrillation, or both, in the right ventricle has resulted in the
identification of various unfavourable outcomes in the context of
tricuspid valve (TV) structure and function.
The tricuspid valve apparatus is a complex structure consisting of
four components: the leaflets (anterior, posterior, and septal), the nonplanar elliptical annulus, two papillary muscles (anterior and poste
rior), and the chordal attachments Fig. 6. Tricuspid regurgitation (TR)
shows signs of worsening due to the effects of prolonged volume over
load, including dilatation of chamber and annulus, tricuspid leaflet
tethering and reduced mobility, and incomplete coaptation. Therefore,
in the presence of left-sided cardiac dysfunction which makes the patient
susceptible to TR, even a slight increase in TR associated with the
presence of a cardiovascular implantable electronic device (CIED) lead
can, with the passage of time, cause severe TR and RH. Our patient had
minimal TR prior to placement of right sided defibrillator lead and it got
worse after that and resulted in right ventricular dysfunction.
As the severity of TR increases, the survival rates plummet, regard
less of ejection fraction or pulmonary artery pressure. The prognosis also
3
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more common with the transvenous ICD [11,12], whereas inappropriate
shocks were more common with the subcutaneous ICD. The risk of
inappropriate shock can be mitigated by selecting the appropriate vector
in case of subcutaneous ICDs [13–15].
Recently, there has been another study done which favor the use of
the subcutaneous ICD for patients with inherited arrhythmia syndromes
and genetic cardiomyopathies who do not need anti-bradycardia pacing
[15]. A meta-analysis Roberto Rodorf et al. demonstrated that in pa
tients with an indication for ICD without the need for pacing, trans
venous ICD and subcutaneous-ICD are overall comparable in terms of
the composite of clinically relevant device-related complications and
inappropriate shock [15].
This case report was drafted in accordance with the SCARE guide
lines [16].

and will be checked).

4. Conclusions

References

Guarantor
Waqas Ullah
Declaration of competing interest
None
Appendix A. Supplementary data
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.amsu.2021.102461.

CIED leads causing tricuspid valve impairment has become increas
ingly recognized over the recent times; however, the evidence under
lying this trend has been derived primarily from retrospective analyses.
In the backdrop of clinical and echocardiographic assessment insinu
ating a diagnosis of the pathology, timely treatment should be carried
out in order to avoid cardiovascular ramifications. In order to circum
vent these issues, leadless pacemakers and subcutaneous ICD devices
should be considered.
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A. Vorobcsuk, J. Kim, H. Afshar, W. Lam, N. Mathuria, M. Razavi, A. Rasekh,
M. Saeed, Subcutaneous versus transvenous implantable defibrillator therapy: a
meta-analysis of case-control studies, JACC Clin Electrophysiol 3 (13) (2017 Dec
26) 1475–1483, https://doi.org/10.1016/j.jacep.2017.07.017. Epub 2017 Sep 27.
PMID: 29759827.
[7] T.F. Brouwer, D. Yilmaz, R. Lindeboom, M.S. Buiten, L.R. Olde Nordkamp, M.
J. Schalij, A.A. Wilde, L. van Erven, R.E. Knops, Long-Term clinical outcomes of
subcutaneous versus transvenous implantable defibrillator therapy, J. Am. Coll.
Cardiol. 68 (19) (2016 Nov 8) 2047–2055, https://doi.org/10.1016/j.
jacc.2016.08.044. PMID: 27810043.
[8] R.E. Knops, L.R.A. Olde Nordkamp, P.-P.H.M. Delnoy, et al., Subcutaneous or
transvenous defibrillator therapy, N. Engl. J. Med. 383 (2020) 526–536.
[9] J.B. van Rees, M.K. de Bie, J. Thijssen, C.J. Borleffs, M.J. Schalij, L. van Erven,
Implantation-related complications of implantable cardioverter-defibrillators and
cardiac resynchronization therapy devices: a systematic review of randomized
clinical trials, J. Am. Coll. Cardiol. 58 (2011) 995–1000.
[10] A.C. van der Heijden, C.J.W. Borleffs, M.S. Buiten, et al., The clinical course of
patients with implantable cardioverter-defibrillators: extended experience on
clinical outcome, device replacements, and device-related complications, Heart
Rhythm 12 (2015) 1169–1176.
[11] G.H. Bardy, W.M. Smith, M.A. Hood, et al., An entirely subcutaneous implantable
cardioverter–defibrillator, N. Engl. J. Med. 363 (2010) 36–44.
[12] A.J. Moss, C. Schuger, C.A. Beck, et al., Reduction in inappropriate therapy and
mortality through ICD programming, N. Engl. J. Med. 367 (2012) 2275–2283.
[13] D.A.M.J. Theuns, T.F. Brouwer, P.W. Jones, et al., Prospective blinded evaluation
of a novel sensing methodology designed to reduce inappropriate shocks by the
subcutaneous implantable cardioverter-defibrillator, Heart Rhythm 15 (2018)
1515–1522.
[14] J. Kuschyk, J. Müller-Leisse, D. Duncker, E. Tülümen, F. Fastenrath, C. Fastner,
M. Kruska, I. Akin, V. Liebe, M. Borggrefe, C. Veltmann, B. Rudic, Comparison of
transvenous vs subcutaneous defibrillator therapy in patients with cardiac
arrhythmia syndromes and genetic cardiomyopathies, Int. J. Cardiol. 323 (2021
Jan 15) 100–105, https://doi.org/10.1016/j.ijcard.2020.08.089. Epub 2020 Aug
29. PMID: 32871189.
[15] Roberto Rordorf, Matteo Casula, Laura Pezza, Federico Fortuni, Antonio Sanzo,
Simone Savastano, Alessandro Vicentini, Subcutaneous versus transvenous
implantable defibrillator: an updated meta-analysis, Heart Rhythm 18 (Issue 3)
(2021) 382–391. ISSN 1547–5271.
[16] R.A. Agha, T. Franchi, C. Sohrabi, G. Mathew, for the SCARE Group, The SCARE
2020 guideline: updating consensus surgical CAse REport (SCARE) guidelines, Int.
J. Surg. 84 (2020) 226–230.

Disclosures
None
Provenance and peer review
Not commissioned, externally peer-reviewed
Ethical approval
Obtained.
Sources of funding
N/A.
Author contribution
MAC and TA: drafted the initial version of the manuscript and con
ducted the literature search. WU and DF: diagnosed the case, proofread
the final draft, and revised it critically
Consent
Written informed consent was obtained from the patient for publi
cation of this case report and accompanying images. A copy of the
written consent is available for review by the Editor-in-Chief of this
journal on request.
Registration of Research Studies
Name of the registry:
Unique Identifying number or registration ID:
Hyperlink to your specific registration (must be publicly accessible

4

